Paraguay is entering an exceptional macroeconomic window. For PBPL, the opportunity is not to send a broad 1,000+ product catalog. It is to select the right entry architecture, the right priority SKUs and the right local route. Paraguay atraviesa una ventana macroeconomica excepcional. Para PBPL, la oportunidad no es enviar un catalogo amplio de mas de 1.000 productos. Es elegir la arquitectura correcta de entrada, los SKUs prioritarios y la ruta local adecuada.
A focused entry beats a broad catalog approach. Una entrada enfocada supera a un abordaje de catalogo general.
PBPL's breadth is a strength, but in Paraguay a broad catalog can dilute negotiation power. The first move should focus on categories where documentation readiness, price logic, regulatory feasibility and partner demand align.La amplitud de PBPL es una fortaleza, pero en Paraguay un catalogo demasiado amplio puede diluir la negociacion. El primer movimiento debe concentrarse en categorias donde documenten, precio, regulacion y demanda del socio esten alineados.
Dry Powder Injections, liquid injections, LVP/SVP and anti-infective lines can create a sharper institutional conversation if dossiers and GMP documentation are ready.DPI, inyectables liquidos, LVP/SVP y anti-infectivos pueden abrir una conversacion institucional mas precisa si los dossiers y la documentacion GMP estan listos.
Antibiotics, antihypertensives, antidiabetics, analgesics and gastro-intestinal products should be filtered by local demand, competition and price defensibility.Antibioticos, antihipertensivos, antidiabeticos, analgesicos y gastro-intestinales deben filtrarse por demanda local, competencia y defensa de precio.
Eye and ear drops, ophthalmic ointments and BFS/SVP capabilities can create differentiated routes if packaging, stability and registration support are clear.Gotas oftalmicas y oticas, unguentos oftalmicos y capacidades BFS/SVP pueden diferenciar la entrada si empaque, estabilidad y registro estan claros.
PBPL's customization, dossier support, batch flexibility and in-house control can support Paraguayan or regional brands looking for reliable Indian manufacturing.La personalizacion, soporte de dossiers, flexibilidad de lote y control interno de PBPL pueden servir a marcas paraguayas o regionales que busquen fabricacion india confiable.
The opportunity is not only market size. It is decision concentration, regulatory navigability and the possibility of using Paraguay as a controlled entry point for selected LATAM expansion.La oportunidad no esta solo en el tamano. Esta en la concentracion de decisiones, la navegabilidad regulatoria y la posibilidad de usar Paraguay como punto controlado para expansion selectiva LATAM.
Pharmaceutical exports: USD 74.7M in 2024 to USD 88.9M in 2025, +18.9% year over year. References: BCP / Agencia IP, IQVIA MAT 12/2025, Cifarma/UIP and public sector estimates.Exportaciones farmaceuticas: USD 74,7M en 2024 a USD 88,9M en 2025, +18,9% interanual. Referencias: BCP / Agencia IP, IQVIA MAT 12/2025, Cifarma/UIP y estimaciones publicas.
Access to Paraguay is not won with a portfolio. It is won with local reading, market intelligence and direct reach to decision-makers.El acceso a Paraguay no se gana con un portafolio. Se gana con lectura local, inteligencia de mercado y llegada directa a quienes deciden.
Scavone, Harrison, Abbott and Megalabs experience across launches, regulation, institutional negotiation and the Paraguayan private healthcare network.Experiencia en Scavone, Harrison, Abbott y Megalabs en lanzamientos, regulacion, negociacion institucional y red privada de salud paraguaya.
The value is not only contact. It is senior access, regulatory judgment, market reading and the ability to convert IQVIA + Close Up + AI into a commercial route.El valor no es solo contacto. Es acceso senior, criterio regulatorio, lectura de mercado y capacidad de convertir IQVIA + Close Up + IA en una ruta comercial.
Partner selection is not a generic distributor search. The market is concentrated across manufacturing, wholesale distribution, pharmacy chains, medical services, insurance and institutional relationships.Seleccionar socio no es buscar distribuidores genericos. El mercado concentra fabricacion, distribucion mayorista, cadenas de farmacia, servicios medicos, seguros y relaciones institucionales.
Phase one should combine speed, risk control, documentation readiness and commercial learning.La fase uno debe combinar velocidad, control de riesgo, documentacion lista y aprendizaje comercial.
An established local company manages registration, distribution and buyer relationships. PBPL brings product breadth, WHO-GMP quality and manufacturing reliability.Un socio local establecido gestiona registro, distribucion y compradores. PBPL aporta amplitud de producto, calidad WHO-GMP y confiabilidad fabril.
Supply selected finished products, dossiers, hospital lines or strategic molecules to local laboratories and importers.Suministro de productos seleccionados, dossiers, lineas hospitalarias o moleculas estrategicas a laboratorios e importadores.
PBPL manufactures under a Paraguayan or regional brand. Ideal for companies seeking scale without investing in manufacturing capacity.PBPL fabrica bajo una marca paraguaya o regional. Ideal para empresas que buscan escala sin invertir en capacidad industrial.
Direct DINAVISA registration of selected PBPL products. Greater control and long-term margin, with higher investment and time.Registro directo DINAVISA de productos PBPL seleccionados. Mayor control y margen de largo plazo, con mayor inversion y tiempo.
Estimates must be validated by product category, dossier status, MOQ, pricing and local partner profile.Las estimaciones deben validarse por categoria, estado documental, MOQ, pricing y perfil de socio local.
| Route | CAPEX | Regulatory risk | Time to entry | Estimated ROI | Recommended |
|---|---|---|---|---|---|
| A - Partnering | Low | Low-Medium | 3-6 months | Medium | Phase 1 |
| B - B2B supply / selected dossiers | Very low | Low | 1-3 months if partner-ready | Medium-High | Phase 1 |
| C - CDMO / contract manufacturing | Low | Low | 3-9 months | High | Phase 1 |
| D - Own brand | High | High | 12-24 months | Maximum | Phase 2 |
For PBPL, speed will depend less on portfolio size and more on documentation readiness, product classification, dossier quality and the right local registration holder.Para PBPL, la velocidad dependera menos del tamano del portafolio y mas de documentacion lista, clasificacion, calidad del dossier y titular local adecuado.
Base framework for manufacturing, import, registration and commercialization. Every product must have a valid DINAVISA certificate.Marco base de fabricacion, importacion, registro y comercializacion. Todo producto debe tener certificado DINAVISA vigente.
Five-year sanitary registration validity. Establishes quality, purity, stability and technical documentation requirements.Vigencia de cinco anos para registro sanitario. Establece requisitos de calidad, pureza, estabilidad y documentacion tecnica.
Regulates pharmacies and dispensing channels. Impacts local partner and distribution strategy.Regula farmacias y canales de dispensacion. Impacta la estrategia de socio y distribucion local.
Complete product data.
Studies, WHO-GMP and origin authorization.
Estimated technical review of 3-6 months.
Registration certificate and market route.
Regulatory recognition mechanism based on prior approvals from reference agencies such as EMA, FDA, ANVISA or INVIMA. It may reduce timelines if PBPL's documentation is prepared and meets applicable criteria.Mecanismo de reconocimiento regulatorio basado en aprobaciones previas de agencias de referencia como EMA, FDA, ANVISA o INVIMA. Puede reducir tiempos si la documentacion de PBPL esta preparada y cumple criterios aplicables.
Potential reduction versus the standard process.Reduccion potencial frente al proceso estandar.
Especially relevant if reference-market documentation is aligned.Especialmente relevante si la documentacion de mercados de referencia esta alineada.
Local DINAVISA reading before introductions are made.Lectura local DINAVISA antes de hacer introducciones.
The advantage must be translated into a segment-by-segment proposition, not a generic capability presentation.La ventaja debe traducirse en una propuesta por segmento, no en una presentacion generica de capacidades.
| Dimension | Local lab | Current importer | PBPL |
|---|---|---|---|
| Competitive pricing | High | Medium | High if MOQ, FOB and category focus align |
| Quality / certifications | Medium | High | WHO-GMP, ISO, international accreditations |
| Portfolio breadth | Localized | Limited by origin | Very high: tablets, capsules, DPI, injections, ophthalmic, syrups |
| CDMO flexibility | Medium-Low | Usually limited | High: customization, partner branding, pack-size flexibility |
| Dossier support | Variable | Variable | CTD / ACTD, query support, renewals and post-approval documentation |
"Driven by Science, Defined by Trust"
Protech Biosystems Pvt. Ltd. is a globally recognized pharmaceutical manufacturer and marketing company with 27+ years of experience, WHO-GMP certification and a broad international export footprint.Protech Biosystems Pvt. Ltd. es una compania farmaceutica de fabricacion y comercializacion reconocida globalmente, con mas de 27 anos de experiencia, certificacion WHO-GMP y amplia huella exportadora.
Turn a market-entry opportunity into an executable strategy.Convertir una oportunidad de entrada en una estrategia ejecutable.
This document: consultant profile, market snapshot, routes, matrix, DINAVISA, Reliance and advisory CTA.Este documento: perfil del consultor, snapshot, rutas, matriz, DINAVISA, Reliance y CTA de consultoria.
Macro context, Scavone/Harrison, AI white spaces with IQVIA + Close Up, price benchmarking and category prioritization.Contexto macro, Scavone/Harrison, espacios blancos IA con IQVIA + Close Up, benchmarking de precios y priorizacion.
Representation, B2B supply, CDMO and own-brand models with P&L, scenarios, risk matrix and ally profile.Modelos de representacion, B2B, CDMO y marca propia con P&L, escenarios, matriz de riesgo y perfil de aliado.
0-3m, 3-12m and 12-36m phases with KPIs, registrations, active prescribers, milestones and owners.Fases 0-3m, 3-12m y 12-36m con KPIs, registros, prescriptores activos, hitos y responsables.
This preview represents the initial 10%. The core value lies in modeling, negotiation and execution.Esta vista previa representa el 10% inicial. El valor central esta en modelado, negociacion y ejecucion.
The real speed will depend on documentation, regulatory classification, commercial conditions and availability of priority SKUs.La velocidad real dependera de documentacion, clasificacion regulatoria, condiciones comerciales y disponibilidad de SKUs prioritarios.
Legal review, representation model, local partner profile, dossier readiness, SKU prioritization and preliminary price logic.
Partner agreements, DINAVISA submissions, pilot lines, first imports and channel relationship building.
Portfolio expansion, regional export platform, margin optimization, market share consolidation and growth KPIs.
Speed to market depends on one simple question: how ready is the documentation for the first 10 priority SKUs?La velocidad de entrada depende de una pregunta simple: que tan lista esta la documentacion de los primeros 10 SKUs prioritarios.
Is Protech Biosystems ready to enter?Esta Protech Biosystems listo para entrar?
I am available to schedule a 30-minute meeting to review the key points, validate PBPL's priority SKUs and define whether a focused Paraguay / LATAM feasibility review makes sense.Quedo disponible para una reunion de 30 minutos para revisar los puntos clave, validar los SKUs prioritarios de PBPL y definir si tiene sentido avanzar a una revision enfocada Paraguay / LATAM.